RA
SCLN

Rational Advisors’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

Rational Advisors’s Portfolio SCLN Stock Details SCLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-10,750
Closed -$140K – 324
2016
Q2 		$140K Buy
+10,750
New +$141K 0.1% 134

Other funds holding SCLN

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Rational Advisors's SCLN Position: Q3 2016 in Review

Rational Advisors sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q3 2016, closing a stake of 10,750 shares — an estimated $140K sold.

Rational Advisors first reported a position in SCLN in Q2 2016 and held it in 1 quarter. The position peaked at $140K in Q2 2016. 151 funds tracked by Wall St. Rank hold SCLN as of Q3 2016.

  • Rational Advisors reported no remaining Sciclone Pharmaceuticals Inc position as of Q3 2016 after selling out during the quarter.
  • Rational Advisors sold 10,750 Sciclone Pharmaceuticals Inc shares in Q3 2016, an estimated $140K.
  • Rational Advisors first reported a position in Sciclone Pharmaceuticals Inc in Q2 2016 and held it in 1 quarter.
  • Rational Advisors's Sciclone Pharmaceuticals Inc position peaked at $140K in Q2 2016.
  • 151 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q3 2016.

Based on Rational Advisors's 13F filing for Q3 2016, filed 10 Nov 2016.